Judy J Chen, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 14 years
- University of Chicago, Pritzker School of Medicine, 2012
Offices
1 location · West Coast Retina Medical Group Inc · 8 clinicians in this group
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (415) 972-4600 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A141948 · Current
Licensed to practise in California · since 2016 · expires 2027-08-31 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Original Medicare doctor bills
$2,872,699
Medicare paid this office $2,872,699 for 1,079 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 250 | $1,438,078 | None |
| Injection, faricimab-svoa, 0.1 mg | 102 | $714,087 | None |
| Injection of drug into eye | 404 | $191,907 | $126 |
| Injection, ranibizumab, 0.1 mg | 42 | $123,096 | None |
| Established patient complete exam of visual system | 695 | $114,891 | $120 |
See all 13 services
| Injection, aflibercept, 1 mg | 250 | $1,438,078 | None |
| Injection, faricimab-svoa, 0.1 mg | 102 | $714,087 | None |
| Injection of drug into eye | 404 | $191,907 | $126 |
| Injection, ranibizumab, 0.1 mg | 42 | $123,096 | None |
| Established patient complete exam of visual system | 695 | $114,891 | $120 |
| Imaging of retina | 1,061 | $100,184 | $40 |
| Injection, aflibercept hd, 1 mg | 11 | $82,382 | None |
| New patient complete exam of visual system | 120 | $16,877 | $141 |
| Compounded drug, not otherwise classified | 51 | $11,406 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $2,759 | $184 |
| Photography of the retina | 53 | $1,960 | $34 |
| Established patient problem focused exam of visual system | 11 | $1,364 | $80 |
| 2d ultrasound scan of eye tissue and structures | 12 | $1,293 | $50 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 1,749 | 1,266 | 1,507 | 1,150 | 1,412 | 1,529 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,079 Original Medicare patients in 2024. Average age 80 · Under 65 2% · 85 and older 29% · Women 60% · Also on Medicaid 13% · Health risk score 1.34. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 73% · Diabetes 25% · Chronic kidney disease 25% · Coronary heart disease 22% · Atrial fibrillation 18% · Cancer 16% · Depression 16% · Heart failure 13% · COPD 10% · Stroke 8% · Dementia 7%.
The office billed $17,800,210, Medicare allowed $3,648,256 and paid $2,872,699; for 35,398 services of 40 kinds; $2,375,580 of it was for drugs given in the office and $497,119 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,079 | 35,398 | 80 | 1.34 | $17,800,210 | $2,872,699 |
| 2023 | 962 | 23,621 | 79 | 1.22 | $12,914,095 | $2,303,092 |
| 2022 | 914 | 10,137 | 79 | 1.25 | $9,326,140 | $1,671,466 |
| 2021 | 1,007 | 8,846 | 79 | 1.24 | $10,872,730 | $1,992,189 |
| 2020 | 728 | 6,801 | 80 | 1.34 | $7,271,470 | $1,318,474 |
| 2019 | 1,053 | 10,384 | 79 | 1.37 | $7,138,878 | $1,743,495 |
| 2018 | 869 | 5,922 | 79 | 1.34 | $3,206,779 | $951,150 |
| 2017 | 101 | 374 | 76 | 1.53 | $264,638 | $80,470 |
| 2016 | 34 | 103 | 76 | 0.92 | $69,938 | $23,331 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection, aflibercept, 1 mg | 221 | $1,223,401 | None |
| Injection, faricimab-svoa, 0.1 mg | 70 | $457,515 | None |
| Injection, ranibizumab, 0.1 mg | 50 | $190,568 | None |
| Injection of drug into eye | 365 | $163,050 | $115 |
| Imaging of retina | 947 | $83,277 | $37 |
| Established patient complete exam of visual system | 564 | $82,036 | $111 |
| Compounded drug, not otherwise classified | 98 | $24,583 | None |
| New patient complete exam of visual system | 136 | $18,088 | $133 |
| Established patient problem focused exam of visual system | 25 | $2,417 | $83 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 11 | $1,610 | $146 |
| Photography of the retina | 32 | $1,125 | $34 |
| 2d ultrasound scan of eye tissue and structures | 11 | $883 | $46 |
2022: 12 services
| Injection, aflibercept, 1 mg | 170 | $996,604 | None |
| Injection, ranibizumab, 0.1 mg | 46 | $180,420 | None |
| Injection of drug into eye | 320 | $126,411 | $110 |
| Injection, faricimab-svoa, 0.1 mg | 30 | $91,314 | None |
| Established patient complete exam of visual system | 548 | $78,394 | $108 |
| Imaging of retina | 874 | $69,079 | $36 |
| Unclassified drugs | 16 | $43,698 | None |
| Compounded drug, not otherwise classified | 135 | $32,764 | None |
| New patient complete exam of visual system | 126 | $16,065 | $127 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 25 | $3,218 | $129 |
| Established patient problem focused exam of visual system | 28 | $2,922 | $75 |
| Photography of the retina | 59 | $1,958 | $33 |
2021: 12 services
| Injection, aflibercept, 1 mg | 129 | $1,256,093 | None |
| Injection, ranibizumab, 0.1 mg | 38 | $223,471 | None |
| Injection of drug into eye | 315 | $175,421 | $116 |
| Imaging of retina | 953 | $90,281 | $37 |
| Established patient complete exam of visual system | 542 | $84,541 | $113 |
| Compounded drug, not otherwise classified | 170 | $61,631 | None |
| New patient complete exam of visual system | 213 | $29,037 | $136 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 55 | $6,740 | $123 |
| Return visit (30+ min) | 82 | $5,185 | $62 |
| Photography of the retina | 100 | $4,179 | $36 |
| New patient visit (45+ min) | 22 | $2,200 | $100 |
| 2d ultrasound scan of eye tissue and structures | 15 | $880 | $49 |
2020: 10 services
| Injection, aflibercept, 1 mg | 101 | $759,324 | None |
| Injection, ranibizumab, 0.1 mg | 39 | $210,103 | None |
| Injection of drug into eye | 319 | $120,442 | $95 |
| Compounded drug, not otherwise classified | 199 | $63,774 | None |
| Imaging of retina | 694 | $60,505 | $34 |
| Established patient complete exam of visual system | 387 | $50,264 | $101 |
| New patient complete exam of visual system | 98 | $11,797 | $120 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 29 | $3,078 | $106 |
| Photography of the retina | 48 | $1,967 | $40 |
| Established patient problem focused exam of visual system | 11 | $1,056 | $81 |
2019: 11 services
| Injection, aflibercept, 1 mg | 98 | $761,400 | None |
| Injection, ranibizumab, 0.1 mg | 107 | $438,608 | None |
| Injection of drug into eye | 366 | $173,134 | $99 |
| Imaging of retina | 989 | $97,536 | $37 |
| Established patient complete exam of visual system | 615 | $91,569 | $108 |
| Compounded drug, not otherwise classified | 257 | $85,965 | None |
| New patient complete exam of visual system | 189 | $24,229 | $128 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 58 | $5,238 | $90 |
| Photography of the retina | 72 | $3,433 | $45 |
| Established patient problem focused exam of visual system | 18 | $1,391 | $77 |
| 2d ultrasound scan of eye tissue and structures | 16 | $1,319 | $60 |
2018: 11 services
| Injection, aflibercept, 1 mg | 72 | $356,792 | None |
| Injection, ranibizumab, 0.1 mg | 60 | $232,618 | None |
| Injection of drug into eye | 340 | $102,271 | $102 |
| Established patient complete exam of visual system | 441 | $65,492 | $114 |
| Imaging of retina | 760 | $60,631 | $39 |
| Compounded drug, not otherwise classified | 230 | $48,824 | None |
| New patient complete exam of visual system | 210 | $28,345 | $135 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 65 | $5,739 | $84 |
| Photography of the retina | 95 | $5,242 | $52 |
| Removal of eye fluid | 12 | $1,020 | $85 |
| 2d ultrasound scan of eye tissue and structures | 11 | $898 | $75 |
2017: 6 services
| Injection, aflibercept, 1 mg | 18 | $32,097 | None |
| Injection, ranibizumab, 0.1 mg | 17 | $28,180 | None |
| Injection of drug into eye | 48 | $4,935 | $101 |
| Established patient complete exam of visual system | 28 | $3,285 | $117 |
| Imaging of retina | 61 | $2,339 | $38 |
| Short return visit (20+ min) | 15 | $1,024 | $60 |
2016: 3 services
| Established patient complete exam of visual system | 19 | $2,434 | $122 |
| Injection of drug into eye | 13 | $1,361 | $105 |
| Imaging of retina | 14 | $625 | $45 |
Medicaid work
$214,248 in 2024
Medicaid paid $214,248 for 1,008 billed services this clinician did in 2024, up to 58 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 327 | $102,885 |
| Aflibercept injection | 68 | $85,470 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 477 | $16,773 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 123 | $8,186 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 13 | $934 |
| 2024 | 1,008 | 5 | 58 | $214,248 |
| 2023 | 1,413 | 7 | 58 | $309,100 |
| 2022 | 969 | 7 | 56 | $103,916 |
| 2021 | 1,134 | 10 | 50 | $87,806 |
| 2020 | 678 | 4 | 54 | $48,853 |
| 2019 | 832 | 4 | 45 | $53,865 |
| 2018 | 198 | 3 | 27 | $12,903 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 468 | $192,935 |
| Aflibercept injection | 50 | $72,287 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 615 | $24,416 |
| Injection, bevacizumab, 10 mg | 114 | $8,545 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 120 | $8,065 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 28 | $1,837 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 18 | $1,015 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 267 | $67,471 |
| Aflibercept injection | 36 | $18,881 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 411 | $11,165 |
| Injection, bevacizumab, 10 mg | 52 | $2,381 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 64 | $2,348 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 36 | $1,664 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 103 | $7 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 343 | $61,857 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 513 | $14,123 |
| Aflibercept injection | 15 | $4,032 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 75 | $2,496 |
| Injection, bevacizumab, 10 mg | 32 | $1,706 |
| Return visit (30+ min) | 33 | $1,538 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 25 | $1,394 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 12 | $508 |
| Compounded drug, not otherwise classified | 14 | $140 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 72 | $11 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 250 | $38,516 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 347 | $8,763 |
| Compounded drug, not otherwise classified | 53 | $837 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 28 | $736 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 284 | $44,656 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 437 | $7,089 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 50 | $1,835 |
| Compounded drug, not otherwise classified | 61 | $285 |
2018
| Clinic visit/encounter, all-inclusive | 28 | $6,529 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 41 | $4,086 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 129 | $2,289 |
Drugs they prescribed that Part D paid
$21,261
Pharmacies billed $21,261 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 304) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
191 generic and 113 brand-name prescriptions · $21,261 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prolensa | 11 | $3,726 | $339 |
| Prednisolone Acetate | 61 | $3,525 | $58 |
| Bromfenac | 18 | $2,717 | $151 |
| Ketorolac Tromethamine | 21 | $411 | $20 |
| Dorzolamide-Timolol | 22 | $269 | $12 |
See all 10 drugs
| Prolensa | 11 | $3,726 | $339 |
| Prednisolone Acetate | 61 | $3,525 | $58 |
| Bromfenac | 18 | $2,717 | $151 |
| Ketorolac Tromethamine | 21 | $411 | $20 |
| Dorzolamide-Timolol | 22 | $269 | $12 |
| Brimonidine | 25 | $227 | $9 |
| Polymyxin B Sul-Trimethoprim | 27 | $215 | $8 |
| Latanoprost | 23 | $158 | $7 |
| Azelastine | 21 | $155 | $7 |
| Timolol Maleate | 11 | $64 | $6 |
Year by year
| 2024 | 304 | 97 | 0% (0) | 37% | $21,261 |
| 2023 | 309 | 119 | None | 41% | $27,751 |
| 2022 | 219 | 92 | None | 46% | $22,993 |
| 2021 | 302 | 111 | 0% (0) | 54% | $27,128 |
| 2020 | 194 | 96 | None | 47% | $14,025 |
| 2019 | 266 | 107 | None | 44% | $19,646 |
| 2018 | 228 | 85 | None | None | $21,576 |
| 2017 | 248 | 72 | None | 46% | $22,053 |
| 2016 | 700 | 180 | 0% (0) | 35% | $51,408 |
| 2015 | 676 | 185 | None | 48% | $66,578 |
| 2014 | 229 | 70 | 0% (0) | 52% | $37,737 |
| 2013 | 76 | 31 | 0% (0) | 39% | $4,947 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Prolensa | 20 | $8,006 | $400 |
| Prednisolone Acetate | 70 | $5,333 | $76 |
| Difluprednate | 15 | $2,195 | $146 |
| Bromfenac | 12 | $1,944 | $162 |
| Moxifloxacin | 18 | $587 | $33 |
| Dorzolamide-Timolol | 23 | $529 | $23 |
| Latanoprost | 15 | $251 | $17 |
| Olopatadine | 13 | $235 | $18 |
| Neomycin-Polymyxin-Dexameth | 11 | $205 | $19 |
| Polymyxin B Sul-Trimethoprim | 21 | $190 | $9 |
| Brimonidine | 12 | $161 | $13 |
2022: 6 drugs
| Prednisolone Acetate | 52 | $3,837 | $74 |
| Timolol Maleate | 13 | $1,338 | $103 |
| Azelastine | 11 | $427 | $39 |
| Latanoprost | 13 | $278 | $21 |
| Dorzolamide-Timolol | 11 | $197 | $18 |
| Polymyxin B Sul-Trimethoprim | 16 | $140 | $9 |
2021: 9 drugs
| Prolensa | 33 | $10,729 | $325 |
| Prednisolone Acetate | 72 | $5,127 | $71 |
| Olopatadine | 11 | $601 | $55 |
| Latanoprost | 20 | $455 | $23 |
| Azelastine | 17 | $421 | $25 |
| Polymyxin B Sul-Trimethoprim | 30 | $251 | $8 |
| Neomycin-Polymyxin-Dexameth | 19 | $248 | $13 |
| Brimonidine | 16 | $214 | $13 |
| Timolol Maleate | 14 | $105 | $8 |
2020: 6 drugs
| Prednisolone Acetate | 29 | $2,282 | $79 |
| Olopatadine | 20 | $1,114 | $56 |
| Azelastine | 18 | $255 | $14 |
| Brimonidine | 11 | $192 | $17 |
| Erythromycin | 12 | $150 | $12 |
| Polymyxin B Sul-Trimethoprim | 16 | $128 | $8 |
2019: 9 drugs
| Prednisolone Acetate | 58 | $4,099 | $71 |
| Prolensa | 13 | $3,599 | $277 |
| Olopatadine | 22 | $1,838 | $84 |
| Brimonidine | 17 | $413 | $24 |
| Polymyxin B Sul-Trimethoprim | 32 | $287 | $9 |
| Neomycin-Polymyxin-Dexameth | 17 | $253 | $15 |
| Ketorolac Tromethamine | 14 | $208 | $15 |
| Timolol Maleate | 15 | $176 | $12 |
| Erythromycin | 15 | $161 | $11 |
2018: 5 drugs
| Prednisolone Acetate | 44 | $2,729 | $62 |
| Dorzolamide-Timolol | 13 | $346 | $27 |
| Brimonidine | 20 | $321 | $16 |
| Polymyxin B Sul-Trimethoprim | 17 | $158 | $9 |
| Timolol Maleate | 16 | $118 | $7 |
2017: 7 drugs
| Travatan Z | 26 | $6,432 | $247 |
| Alphagan P | 20 | $4,196 | $210 |
| Zioptan | 11 | $2,039 | $185 |
| Dorzolamide-Timolol | 32 | $919 | $29 |
| Latanoprost | 35 | $540 | $15 |
| Brimonidine | 20 | $238 | $12 |
| Timolol Maleate | 19 | $122 | $6 |
2016: 15 drugs
| Travatan Z | 40 | $9,382 | $235 |
| Combigan | 23 | $5,267 | $229 |
| Prednisolone Acetate | 46 | $3,664 | $80 |
| Lumigan | 12 | $2,396 | $200 |
| Brimonidine | 66 | $2,051 | $31 |
| Latanoprost | 151 | $1,968 | $13 |
| Pataday | 12 | $1,924 | $160 |
| Dorzolamide-Timolol | 94 | $1,718 | $18 |
| Pilocarpine | 20 | $830 | $42 |
| Doxycycline Hyclate | 15 | $737 | $49 |
| Ketorolac Tromethamine | 27 | $546 | $20 |
| Dorzolamide | 23 | $379 | $16 |
| Erythromycin | 34 | $304 | $9 |
| Timolol Maleate | 31 | $271 | $9 |
| Polymyxin B Sul-Trimethoprim | 13 | $120 | $9 |
2015: 14 drugs
| Travatan Z | 57 | $11,199 | $196 |
| Restasis | 15 | $8,698 | $580 |
| Azopt | 21 | $5,568 | $265 |
| Combigan | 24 | $4,653 | $194 |
| Alphagan P | 24 | $4,637 | $193 |
| Pataday | 14 | $4,604 | $329 |
| Brimonidine | 59 | $2,766 | $47 |
| Prednisolone Acetate | 50 | $2,626 | $53 |
| Dorzolamide-Timolol | 65 | $2,008 | $31 |
| Latanoprost | 102 | $1,670 | $16 |
| Timolol Maleate | 45 | $1,362 | $30 |
| Pilocarpine | 17 | $1,064 | $63 |
| Dorzolamide | 37 | $676 | $18 |
| Erythromycin | 35 | $444 | $13 |
2014: 8 drugs
| Travatan Z | 19 | $3,669 | $193 |
| Pataday | 19 | $3,073 | $162 |
| Lumigan | 11 | $2,817 | $256 |
| Brimonidine | 25 | $1,367 | $55 |
| Prednisolone Acetate | 16 | $1,004 | $63 |
| Latanoprost | 45 | $648 | $14 |
| Dorzolamide-Timolol | 25 | $514 | $21 |
| Erythromycin | 14 | $218 | $16 |
Money from drug and device companies
$7,758 in 2025
| 2025 | 8 | 25 | $6,325 | $7,758 |
| 2024 | 5 | 16 | $2,640 | $3,500 |
| 2023 | 5 | 12 | None | $507 |
| 2022 | 4 | 11 | None | $760 |
| 2021 | 2 | 5 | $1,980 | $2,071 |
| 2020 | 2 | 4 | None | $92 |
| 2019 | 4 | 9 | None | $374 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Vabysmo | $6,411 | 9 payments
|
| Genentech | Susvimo | $730 | 1 payment
|
| Alcon Vision | Hydrus Microstent | $229 | 2 payments
|
| ANI Pharmaceuticals | Yutiq | $170 | 6 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $122 | 4 payments
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $38 | 1 payment
|
See all 25 published payments
| Regeneron Healthcare Solutions | Meals · 2025-12-16 | Eylea Hd | $32 |
| Genentech | Consulting · 2025-12-15 | Susvimo | $730 |
| Genentech USA | Meals · 2025-12-09 | Vabysmo | $35 |
| ANI Pharmaceuticals | Meals · 2025-11-18 | Iluvien | $32 |
| Alcon Vision | Meals · 2025-10-22 | Hydrus Microstent | $90 |
| ANI Pharmaceuticals | Meals · 2025-09-23 | Iluvien | $23 |
| Genentech USA | Meals · 2025-09-16 | Vabysmo | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-08-26 | Eylea Hd | $32 |
| Astellas Pharma US | Meals · 2025-08-19 | Izervay | $30 |
| Genentech USA | Meals · 2025-07-29 | Vabysmo | $25 |
| Genentech USA | Travel · 2025-07-29 | Vabysmo | $126 |
| Genentech USA | Consulting · 2025-07-29 | Vabysmo | $5,595 |
| Genentech USA | Meals · 2025-07-29 | Vabysmo | $213 |
| Genentech USA | Travel · 2025-07-29 | Vabysmo | $320 |
| ANI Pharmaceuticals | Meals · 2025-07-08 | Yutiq | $20 |
| ANI Pharmaceuticals | Meals · 2025-05-10 | Yutiq | $33 |
| Regeneron Healthcare Solutions | Meals · 2025-04-29 | Eylea Hd | $26 |
| Genentech USA | Meals · 2025-04-15 | Vabysmo | $29 |
| Johnson & Johnson Surgical Vision | Meals · 2025-04-09 | Tecnis Iol | $38 |
| ANI Pharmaceuticals | Meals · 2025-03-11 | Yutiq | $31 |
| Alcon Vision | Meals · 2025-02-28 | Hydrus Microstent | $140 |
| Regeneron Healthcare Solutions | Meals · 2025-02-04 | Eylea Hd | $32 |
| Genentech USA | Meals · 2025-01-28 | Vabysmo | $35 |
| ANI Pharmaceuticals | Meals · 2025-01-14 | Purified Cortrophin Gel | $31 |
| Abbvie | Meals · 2025-01-09 | Ozurdex | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,500
| Genentech USA | Susvimo | $3,332 | 10 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $91 | 3 payments
|
| Bausch & Lomb Americas | Xipere | $31 | 1 payment
|
| Carl Zeiss Meditec USA | None | $30 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea Hd | $16 | 1 payment
|
2023: $507
| Alcon Vision | Hydrus Microstent | $145 | 3 payments
|
| Genentech USA | Vabysmo | $139 | 5 payments
|
| Bausch & Lomb Americas | Xipere | $131 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $61 | 2 payments
|
| AbbVie | Durysta | $30 | 1 payment
|
2022: $760
| Alcon Vision | Hydrus Microstent | $498 | 4 payments
|
| Abbvie | Xen Glaucoma Treatment System | $139 | 2 payments
|
| Genentech USA | Vabysmo | $105 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $18 | 1 payment
|
2021: $2,071
| Genentech USA | Lucentis | $2,045 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $26 | 1 payment
|
2020: $92
| Genentech USA | Lucentis | $74 | 3 payments
|
| Genentech | Lucentis | $17 | 1 payment
|
2019: $374
| Genentech | Lucentis | $213 | 3 payments
|
| Carl Zeiss Meditec | None | $70 | 1 payment
|
| Novartis Pharmaceuticals | Durezol | $60 | 3 payments
|
| Genentech USA | Lucentis | $31 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Va2 Phiii Yosemite · 2020 | Their institution | $158,108 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2019 | Their institution | $109,157 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2021 | Their institution | $105,528 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019 | Their institution | $92,477 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022 | Their institution | $84,698 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020 | Their institution | $77,856 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021 | Their institution | $57,963 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020 | Their institution | $42,767 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021 | Their institution | $30,871 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022 | Their institution | $21,573 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023 | Their institution | $21,088 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023 | Their institution | $14,838 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019 | Their institution | $12,444 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021 | Their institution | $10,782 |
| Boehringer Ingelheim International GmbH · A Randomized, Double-Masked, Placebo-Controlled Trial To Evaluate the Efficacy, Safety and Tolerability of Oral Bi1815368 in Participants With Center-Involved Diabetic Macular Edema · 2025 | Their institution | $889 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 70.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265875611
- Licence
- CA A141948California A141948: Current · expires 2027-08-31
- Trained
- University of Chicago, Pritzker School of Medicine, 2012 · 14 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1445 Bush St, San Francisco, CA, 94109
- NPI first listed
- 2013-04-15
- NPI last updated
- 2020-08-21
- NPI record certified
- 2020-08-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 100 Tamal Plz Ste 120, Corte Madera, CA, 94925 · 400 30th St Ste 402, Oakland, CA, 94609 · 101 S San Mateo Dr Ste 306, San Mateo, CA, 94401 · 1981 N Broadway Ste 265, Walnut Creek, CA, 94596
This office lists an electronic records connection.